of 24/24
Uncorrected proofs — not for distribution 5 A Latin American “Point de Vue” on the Epidemiology, Control, and Treatment Options of Infections Caused by Extended-spectrum Beta-lactamase Producers José Maria Casellas and Mirta G. Quinteros Abstract Soon after the introduction of the third- generation cefalosporins (3GC) in the 1980s, plasmidic beta-lactamases derived from the so-called broad-spectrum beta- lactamases (BSBLs, which are able to hy- drolyze first- and some second-generation cephalosporins, amino-, ureido- and car- boxy-penicillins) such as TEM-1, SHV-1 and others, appeared and were shown to be capable of hydrolyzing monobactams, beta- lactam/beta-lactamase inhibitor combina- tions and in some instances fourth-genera- tion cephalosporins (4GC) as well. ese new enzymes were denominated extend- ed-spectrum beta lactamases (ESBLs) and they are derived from BSBLs. ree ES- BLs families are predominant: TEM-de- rived (Europe and the US); SHV-derived (worldwide), and CTX-M, which were first detected in Argentina and later on in Eastern Europe and are nowadays glob- ally extended. While TEM-derived ES- BLs hydrolyze preferentially ceftazidime, SHV-type hydrolyze both ceftazidime and cefotaxime; CTX-M preferentially hydro- lyze cefotaxime and 4GC. ESBLs are fre- quently present in megaplasmids and carry several genes determining resistance to other antibiotics. Difficulties in screening for ESBLs lasted a decade and were due to the fact that NCCLS was reluctant to recommend phenotypic methods includ- ing cefotaxime, and also considered that investigation of ESBLs should only be performed in Escherichia coli and Klebsiella spp. isolates. Latin America is presently the region showing the higher incidence of ES- BLs. Low income level and other social is- sues, crowed hospitals, prolonged hospital stay, as well as the increasing use of invasive devices are factors increasing the risk for ESLB-producer infections. Previous use of 3GC, 4GC, fluoroquinolones, and amino- glycosides are also important factors. Per- haps even high inocula in infections such as abscesses could also be responsible for the selection of ESBL-producing organ- isms causing difficulties in clinical treat- ments. ESBL producers are only uniformly susceptible, in human infections, to car- bapenems and tigecycline. Introduction Many bacteria possess enzymatic mecha- nisms that allow them to inactivate differ- ent antibacterial drugs (i.e., aminoglyco- side inactivating enzymes, chlorampheni- col acetyltransferases, beta-lactamases (BLAs), etc.) Most of these enzymes are produced by the same bacterial species which synthesize the antibacterial com- pounds themselves. BLAs are the most common and widely distributed among an-

A Latin American “Point de Vue” on the Epidemiology ...*IMP family; VIM family; GIM family; SPM-1 *KPC family *OXA family P or C Same substrates as for ESBLs plus cephamycins and

  • View

  • Download

Embed Size (px)

Text of A Latin American “Point de Vue” on the Epidemiology ...*IMP family; VIM family; GIM family;...

  • Uncorrected proofs — not for distribution

    5A Latin American “Point de Vue” on the Epidemiology, Control, and Treatment Options of Infections Caused by Extended-spectrum Beta-lactamase ProducersJosé Maria Casellas and Mirta G. Quinteros

    AbstractSoon after the introduction of the third-generation cefalosporins (3GC) in the 1980s, plasmidic beta-lactamases derived from the so-called broad-spectrum beta-lactamases (BSBLs, which are able to hy-drolyze first- and some second-generation cephalosporins, amino-, ureido- and car-boxy-penicillins) such as TEM-1, SHV-1 and others, appeared and were shown to be capable of hydrolyzing monobactams, beta-lactam/beta-lactamase inhibitor combina-tions and in some instances fourth-genera-tion cephalosporins (4GC) as well. These new enzymes were denominated extend-ed-spectrum beta lactamases (ESBLs) and they are derived from BSBLs. Three ES-BLs families are predominant: TEM-de-rived (Europe and the US); SHV-derived (worldwide), and CTX-M, which were first detected in Argentina and later on in Eastern Europe and are nowadays glob-ally extended. While TEM-derived ES-BLs hydrolyze preferentially ceftazidime, SHV-type hydrolyze both ceftazidime and cefotaxime; CTX-M preferentially hydro-lyze cefotaxime and 4GC. ESBLs are fre-quently present in megaplasmids and carry several genes determining resistance to other antibiotics. Difficulties in screening for ESBLs lasted a decade and were due to the fact that NCCLS was reluctant to

    recommend phenotypic methods includ-ing cefotaxime, and also considered that investigation of ESBLs should only be performed in Escherichia coli and Klebsiella spp. isolates. Latin America is presently the region showing the higher incidence of ES-BLs. Low income level and other social is-sues, crowed hospitals, prolonged hospital stay, as well as the increasing use of invasive devices are factors increasing the risk for ESLB-producer infections. Previous use of 3GC, 4GC, fluoroquinolones, and amino-glycosides are also important factors. Per-haps even high inocula in infections such as abscesses could also be responsible for the selection of ESBL-producing organ-isms causing difficulties in clinical treat-ments. ESBL producers are only uniformly susceptible, in human infections, to car-bapenems and tigecycline.

    IntroductionMany bacteria possess enzymatic mecha-nisms that allow them to inactivate differ-ent antibacterial drugs (i.e., aminoglyco-side inactivating enzymes, chlorampheni-col acetyltransferases, beta-lactamases (BLAs), etc.) Most of these enzymes are produced by the same bacterial species which synthesize the antibacterial com-pounds themselves. BLAs are the most common and widely distributed among an-

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros10� |

    tibacterial inactivating enzymes. Although first discovered in a Gram-positive species (the staphylococcal penicillinases), BLAs constitute the major defense of Gram-neg-ative bacteria against beta-lactam antibiot-ics ( Jacoby and Muñoz-Price, 2005). Most BLAs are ancient enzymes, and it was soon observed that at least two of them have a separate heritage (Garau et al., 2004). One group is the so-called serine enzymes which have a serine residue at the active site, just as penicillin binding proteins (PBPs); it is supposed that these BLA probably evolved from the PBPs over the past 2 billion years (Medeiros, 1997). The other ancient BLA group are the metallo-enzymes which use a metallic ion, preferentially zinc, as a cofac-tor (Livermore, 1995).

    After the introduction of beta-lactam antibiotics for clinical human and vet-erinary usage, new BLAs appeared in the late 1950s in common, clinically relevant Gram-negative bacilli such as Escherichia coli, Klebsiella spp. and other enteric bac-teria (Livermore, 1995; Medeiros, 1997; Jacoby and Muñoz-Price, 2005). These enzymes hydrolyzed efficiently ampicillin and in some cases first-generation cephalo-sporins. Their hydrolytic spectrum was en-larged compared with those of penicillinas-es and were therefore denoted “broad-spec-trum beta lactamases” (BSBLs) (Casellas and Goldberg, 1989; Livermore, 1995; Bush et al., 1995). Later on, in the 1970s, BSBLs spread to bacterial species that pre-viously did not produced any BLA such as Haemophilus spp. and Neisseria gonorrhoe-ae. During the 1980s a plethora of new an-tibiotics were introduced, particularly new, “third-generation” cephalosporins (3GCs) having an extended spectrum and activity to treat infections caused by enteric bac-teria (Enterobacter spp., Serratia spp., etc.) or non-fermentative Gram-negative bacilli (as Pseudomonas spp.). Soon after, BLAs

    capable of hydrolyzing 3GCs were discov-ered; they were named “extended-spectrum beta-lactamases” (ESBLs). The properties, origins, epidemiology, laboratory detection of ESBLs as well as recommendations for treating the infections to which they are as-sociated are the topic of this review. Other BLAs, such as AmpC, or metallo-beta-lac-tamases will not be considered. The geno-typic characterization of beta-lactamases by molecular methods are also out of the scope of this chapter.

    Rationale of the classification of BLAsEven dealing exclusively with ESBLs, a brief review of the classification of BLAs is mandatory in order to understand their origin and relation with other beta-lac-tamases. A list of all the different BLAs that have been described up to this date is an almost impossible task. A functional classification arrangement of BLAs has been provided by Bush et al. (1995). Hun-dreds of BLAs have been added to that ar-rangement and as the amino acid sequenc-ing of BLAs is nowadays readily available, the list is increasing permanently. A web-site allows specialists to be aware about in-formation related to the new BLAs (www.lahey.org/studies/wbt.stm), particularly their amino acid sequences. Fortunately, a simpler and rational classification is avail-able due to Ambler et al. (1992); it is called “molecular classification” since it is based on the molecular weight of the BLA and the amino acid residue present at the ac-tive site. Based on Ambler’s scheme and including the inhibitory activity of clavu-lanic acid, Jacoby and Muñoz-Price (2005) published recently a simple classification using the “familiar names” used by infec-tious diseases physicians as well as clinical microbiologists. We added here the com-mon codification site of the enzymes (plas-

  • Tab

    le �

    .1 B




    es fr

    om G




    e b




    e of


    a la








    ic (P

    ) or


















    r cl



    ad s







    M 1

    ; TE


















    C, 2






    P o

    r C




    A fa






    ed s







    M fa




    as B


    Ls +


    C a








    V fa






    -M fa





    s ce





    t en










    as S




    M fa






    A fa




    as C







    al a


    C fr





    r sp














    C, 2


    , cep



    s. W













    ic a




    -1; A


    1; C


    ; CM



    ily; D




    X fa





    ; MIR

    -1; M









    as fo

    r E


    Ls p














    ily; V

    IM fa


    ; GIM



    ; SP







    A fa


    P o

    r C


    e su



    s as





    s ce















    r re







    of T









    as fo

    r B


    L b










    1 BE




    ily; P



    ily; S




    ily; T



  • Uncorrected proofs — not for distribution

    Casellas and Quinteros10� |

    midic or chromosomic) and characteristic resistance traits (Table 5.1).

    Origin and general properties of ESBLsBLAs cleave the amide bond of the beta-lactam ring. Consequently, beta-lactams are not more able to bind to PBPs and can not block the synthesis of the cell wall, thus rendering beta-lactams harmless to bacteria. BSBLs are able to open the amide bond of penicillin, aminopenicillins and also, but not generally, of first-generation cephalosporins, carboxypenicillins, and ureidopenicillins. BLA inhibitors such as clavulanate, sulbactam or tazobactam are capable of preventing the activity of BSBLs by binding irreversibly to these enzymes. The structure of oxyminocephalosporins (3GCs), such as ceftazidime, cefotaxime, ceftriaxone and ceftizoxime, as well as monobactams, does not allow them to ac-cess BSBLs’ active site in a position that permits the enzyme’s serine and a water molecule to provoke the hydrolysis of the beta-lactam amide bond. However, if a positional change of the serine responsible for the cleavage of the cephalosporin amide bond occurs, then hydrolysis of the 3GC is possible. This was observed for the first time in 1983 at Prahmod Shah’s laboratory at Frankfurt (Knothe et al., 1983). That enzyme was further studied in 1985 and proved to be derived from a BSBL, SHV-1, and named SHV-2 (Kliebe et al., 1985). The serine at position 238 in SHV-1 was found to be replaced by glycine in SHV-2, and that was found to be the cause of the enhanced activity against 3GCs (in fact, this reportedly first ESBL isolate was not really the first one: on 1981, in the labora-tory of one of us ( JMC) at Buenos Aires, we were participating in a study aimed to use amikacin as the sole aminoglycoside at the “Hospital del Docente” looking to re-

    duce gentamicin resistance. Simultaneous-ly, cefotaxime was being used in phase-III trials. One K. pneumoniae isolate resistant to amikacin proved to be resistant to cefo-taxime as well, and resistance to both anti-bacterials showed to be transferable. That ESBL was later described as an SHV-5 ESBL (Casellas and Goldberg 1989; Ca-sellas et al., 1990; Casellas, 1999; Paterson and Bonomo, 2005). Amikacin resistance was due to APH-3′ and AAC-6′ enzymes (G. Miller, unpublished data) that were encoded in the same megaplasmid, along with the SHV-5 gene).

    With the exception of a few ESBLs of the OXA family which appertain to the Ambler class D, that are weakly inhibited by clavulanate, all other ESBLs belong to the Ambler class A and are strongly inhib-ited by clavulanate. They belong to the 2e group of the Bush et al. (1995) BLA clas-sification, which includes plasmid-medi-ated enzymes. They can be classified on the basis of their hydrolytic activity against ceftazidime (ceftazidimases) or cefotaxi-me/ceftriaxone (cefotaximases), which in turn relates to the tertiary structure of the enzyme (Huang et al., 1996). Nonetheless, class A BLAs are a very heterogeneous mo-lecular group, sharing a wide range of se-quence identity (20 to 99%; Jacoby, 1994). ESBLs are widely distributed in a variety of Enterobacteriaceae, even among AmpC producers, as well as in non-fermentative Gram-negative bacilli, Vibrio spp. (Petroni et al., 2002), Aeromonas spp. (Quinteros et al., 2000), Capnocytophaga spp., etc. (Bradford, 2001).

    ESBLs are frequently encoded by large, multicopy plasmids; the presence of highly active promoters is also common. In some circumstances, as in the case of K. pneumoniae isolates, decreased expres-sion of outer membrane porins along with ESBL production, confer resistance to an-

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 10�

    tibiotics such as cefepime, which are not greatly affected by TEM- or SHV-derived ESBLs ( Jacoby, 1994, Jacoby and Muñoz-Price, 2005, Bradford, 2001). The genes encoding ESBLs may also be located in the chromosome and may be carried by trans-posons ( Jacoby, 1994), and other ESBL genes, as those encoding CTX-M enzymes, are often found in integrons ( Jacoby and Muñoz-Price, 2005, Bradford, 2001).

    ESBL definitionESBLs are BLA enzymes able to hydrolyze penicillins, cephalosporins—in some cases including fourth-generation ones (4GC) such as cefepime or cefpirome—and monobactams. They are not able to hydro-lyze cephamycins (e.g., cefoxitin, cefotetan) nor carbapenems. ESBLs characteristi-cally hydrolyze 3GCs and monobactams and, in some cases, 4GCs, at rates that are at least 10% of that for benzylpenicillin. They are inhibited by clavulanate, thus dis-tinguishing them from AmpC (group 1) BLAs produced by Enterobacter cloacae, E. aerogenes, Citrobacter freundii and Serratia marcescens (Bush et al., 1995) although it must be considered that some AmpC pro-ducers can harbor plasmids codifying for ESBLs as well.

    Different ESBLs families

    TEM-type ESBLsTEM-1 has been the most frequently en-countered ESBL since its first report in 1965. The enzyme was found to be codi-fied by a plasmid of an Escherichia coli clini-cal isolate resistant to ampicillin, sent from Athens, Greece, to Naomi Datta’s labora-tory at London. The name of the patient was Temoniera, therefore the designa-tion as TEM-1 (Datta and Kontomicha-lou, 1965; Paterson and Bonomo, 2005). At least 90% of E. coli isolates resistant

    to penicillins harbor this pI 5.4 enzyme. TEM-2 (pI 5.6) is very similar to TEM-1 but is less frequent. It is not surprising that single amino acid changes in both TEM-1 and TEM-2 BSBLs were the origin of the most frequent ESBLs found in Europe and the USA ( Jacoby and Muñoz-Price, 2005) (an entirely different origin for TEM and SHV ESBLs is also briefly discussed in Chapter 7). TEM enzymes comprises nearly 140 different ESBLs (see website, above). One of the reasons for the expand-ed distribution of TEM ESBLs is that they seem to emerge quite easily by point muta-tions, as they are also easily created in the laboratory ( Jacoby, 1994; Jacoby and Mu-ñoz-Price, 2005). Modifications of the ac-tive site of the TEM enzymes facilitate ac-cess to oxymino-beta-lactams, as has been proved by crystallographic studies (Knox, 1995; Jacoby and Muñoz-Price, 2005). There are two TEM-ESBL families, one derived from TEM-1 and other derived from TEM-2.

    Most of the TEM-derived ESBLs are more active against ceftazidime than against cefotaxime or ceftriaxone. Unfortunately, up to 1998, the National Committee for Clinical Laboratory Standards (NCCLS, now Clinical Laboratory Standards Institute, CLSI) recommended that the laboratory test for detecting ESBLs in the USA should be performed using cef-tazidime as substrate; that is why many isolates producing cefotaximase ESBLs (CTX-family and some TEM-derived) were probably not detected ( Jacoby 1994; Rossi et al., 1995; Bradford, 2001; Casellas et al., 2003; Quinteros et al., 2003; Paterson et al., 2003; Bonnet, 2004; Paterson and Bonomo, 2005). TEM-10 and TEM-26 are among the most common TEM-ESBLs in the USA and many European countries ( Jacoby and Muñoz-Price, 2005). Jacoby and Muñoz-Price (2005)

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros10� |

    recently stated that they are also frequent in South America. However, TEM deriva-tives are actually seldom found in South America (Casellas et al., 2003; Quinteros et al., 2003): a paper from Paterson et al. (2003) was cited by Jacoby addressing this point; Paterson et al. found TEM-10 and TEM-12 ESBLs in two isolates that one of us ( J.M.C.) sent to them. When we read the paper we looked at the patients’ clini-cal history and found that both were recent flyers from Miami where both were hospi-talized for 2–5 days. We still think that, whatever the reason, TEM-ESBL enzymes are uncommon in southern South America while frequent in the USA.

    SHV-type ESBLsAs previously mentioned, SHV-type en-zymes were the first discovered ESBLs (Knothe et al., 1983) and SHV-1 is the parental BSBL common in Klebsiella pneu-moniae isolates. The enzyme was originally chromosomal but it has been presently found in plasmids ( Jacoby and Muñoz-Price, 2005). SHV family ESBLs produc-ers are all derived from SHV-1, by point mutations (one or two changed amino acids). SHV-5 and SHV-12 are prevalent in the USA while SHV-2 and SHV-5 are prevalent in Europe and Latin America (Casellas, 1999; Bradford, 2001; Casellas et al., 2003; Quinteros et al., 2003; Pater-son et al., 2003; Jacoby and Muñoz-Price, 2005). More than 50 SHV ESBLs variants have been described so far (http://www.la-hey.org/studies/webr.htm). Recently, out-breaks of SHV-producing Acinetobacter spp. and Pseudomonas aeruginosa isolates have been reported (Poirel et al., 2004; Pa-terson and Bonomo, 2005).

    CTX-M type ESBLsIn the late 1980s, two reports of non-SHV, non-TEM ESBLs were published. In Ja-

    pan, in 1986, a new ESBL was discovered and designated as FEC-1 (Bonnet, 2004), in a cefotaxime-resistant E. coli. However, the isolate was not obtained from human clinical specimens but instead from the fe-ces of a laboratory animal, and the report was mostly ignored, although mentioned in the very complete review of the CTX M family by Bonnet (2004). In 1990, Bauern-feind et al. (1992), from Munich University, reported an E. coli clinical isolate obtained in East Germany which produced a non-SHV, non-TEM ESBL which hydrolyzed cefotaxime but not ceftazidime, therefore the enzyme was denominated CTX M-1 thus creating the “cefotaximase family” (CTX-M family).

    During the period 1990–92 numerous reports were presented in Argentina quot-ing outbreaks due to invasive Salmonella enterica var. Typhimurium producing sep-sis and meningitis, particularly in children (Casellas et al., 1990; Rossi et al., 1995). An isolate recovered in our laboratory ( J.M.C.), showing a typical ESBL pheno-type, was highly resistant to cefotaxime (MIC > 64 mg/L), but notably susceptible to ceftazidime (MIC 0.5 mg/L). The strain was inhibited by clavulanate and the pI of the enzyme was alkaline (8.2). The isolate was sent to A. Bauernfeind, who sequenced the encoding gene and proved it related to CTX M-1 and therefore was named as CTX M-2 (Bauernfeind, 1992; Casellas, 1999). The plasmid codifying CTX M-2 thereafter spread to other non-typhoid Salmonella, and Klebsiella (Casellas, 1999; Paterson et al., 2003; Bonnet, 2004). By now, CTX M-2 is by far the prevalent ESBL in Argentina (Radice et al., 2002; Casellas et al., 2003; Quinteros et al., 2003; Paterson et al., 2003; Rodríguez et al., 2005). By 1992, CTX M-2 producers accounted for up to 20–30% of Klebsiella pneumoniae cephalosporin resistance in

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 107

    Argentina (Bradford, 2001; Radice et al., 2002; Quinteros et al., 2003; Rodríguez et al., 2005) and in 2005 up to 40%, 25% E. coli, 20% P. mirabilis and many other Enterobacteriaceae including AmpC pro-ducers. Most Salmonella spp. and Shigella spp. isolates that are ESBL producers, ex-press CTX M-2 type enzymes (Radice et al., 2002; Quinteros et al., 2003; Rodríguez et al., 2005).

    After isolating the first CTX-M ESBL producers in Argentina and East Europe, and as the existence of these plasmid en-zymes with high pIs was known, NCCLS decided to suggest that the phenotypic as-say with clavulanate for ESBLs presump-tive detection should be performed not only with ceftazidime but also with cefo-taxime. Consequently, cefotaximase detec-tion increased and CTX-M enzymes begun to be considered not so exotic ESBLs and were referenced globally later on (Bonnet et al., 2004; Paterson and Bonomo, 2005). CTX-M BLAs are by now exceeding 40 different types, and can be classified into five clusters based on their amino acid se-quence relations (Bradford, 2001; Bonnet, 2004; Jacoby and Muñoz-Price 2005):

    • group 1: CTX-M-1 cluster including plasmid-mediated CTX-M-1, 3, 10, 12, 15, 22, 23, 28, 30 and FEC-1;

    • group 2: CTX-M-2 cluster including plasmid-mediated CTX-M-2, 4, 5, 6, 7, 20 and TOHO-1;

    • group 3: CTX-M-8 group which in-cludes plasmid-mediated CTX-M-8 alone;

    • group 4: CTX-M-9 group including plasmid-mediated CTX-M-9, 13, 14, 16, 17, 19, 21, 27 and TOHO-2

    • group 5:) CTX-M-25 group includes CTX-M-25 and CTX-M-26.

    CTX-M enzymes are derived from the mobilization of chromosomal en-zymes of infrequently isolated species of Enterobacteriaceae of the genera Kluyvera to plasmids of other genera. The group of Kluyvera BLAs are designed KLU: KLUA from K. ascorbata (Oliver et al., 2001; Humeniuk et al., 2002; Poirel et al., 2002; Bonnet, 2004); KLUG from K. georgiana (Poirel et al., 2002); KLUC from K. cryo-crescens (Decousser et al., 2001). It has been shown that chromosomal KLUA found in CTX-M-3 is the possible origin of the first CTX-M enzyme that is CTX-M-1 (Bonnet, 2004). The homology between KLUG-1 and CTX-M-8 is remarkable since they share 99% amino acid identity. Of note, CTX-M enzymes share no more than 40% identity with TEM or SHV ESBLs (Paterson and Bonomo, 2005).

    Strains expressing CTX-M type BLA, in addition to the general feature of their more rapid hydrolysis of cefotaxime and ceftriaxone, are better inhibited by tazo-bactam than by sulbactam or clavulanate (Bradford, 2001; Casellas et al., 2003; Quinteros et al., 2003; Bonnet, 2004; Paterson and Bonomo, 2005), which may explain the higher sensitivity of some CTX-M producers to piperacillin–tazo-bactam than to cefepime (Tzouvelekis et al., 2000; Yu et al., 2002; Casellas et al., 2003; Quinteros et al. 2003; Paterson et al., 2003).

    CTX-M encoding genes have com-monly been located on plasmids with vary-ing sizes (7 to 160 kb). CTX-M-2, the most frequent in South America is generally encoded in megaplasmids (Bonnet, 2004; Jacoby and Muñoz-Price, 2005; Paterson and Bonomo, 2005). These plasmids carry genes for resistance to multiple other an-tibiotics including aminoglycosides, chlor-amphenicol, trimethoprim, sulfonamides

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros10� |

    and tetracyclines, and the clinical use of these antimicrobials can select for entero-bacterial CTX-M producers (Casellas et al., 2003; Paterson et al., 2003; Paterson and Bonomo, 2005). CTX-M plasmids are frequently transmissible by conjuga-tion in vitro, a fact that could explain the rapid dissemination of CTX-M harbor-ing plasmids. In CTX-M-2, a class 1 in-tegron located in a conjugative plasmid of Salmonella enterica serovar Typhimurium has been detected (Radice et al., 2002).

    PER type ESBLsPER enzymes share low homology (25–27%) with TEM, SHV, or CTX-M en-zymes (Nordman et al., 1994; Bauernfeind et al., 1996; Paterson and Bonomo, 2005). These enzymes hydrolyze penicillins and cephalosporins and are inhibited by cla-vulanate (Bauernfeind et al., 1996). They efficiently hydrolyze cefotaxime and cef-triaxone as well as ceftazidime. Two PER enzymes are known at present from very different geographic areas. PER-1 was first detected in P. aeruginosa, Salmonella spp., and Acinetobacter spp. from Turkey (Nord-man et al., 1994; Bauernfeind et al., 1996; Vahaboglu et al., 2001). PER-1 appears to be endemic in Turkey since as many as 11% of P. aeruginosa isolates were found to produce PER-1 in this country (Vahabo-glu et al., 1995, 1998).

    PER-2 was first detected from an iso-late of S. enterica recovered in our laborato-ry ( J.M.C.) at Buenos Aires (Bauernfeind et al., 1996). Later it was detected from several Enterobacteriaceae and even from Vibrio cholerae El Tor (Rossi et al., 1995; Petroni et al., 2002). PER-2 shows 86% homology with PER-1 (Vahaboglu et al., 1998; Bonnet, 2004; Paterson and Bonomo, 2005) but seems to be restricted to Argentina and border countries such as Chile, Paraguay, and Uruguay. We received

    isolates from Chile (from J. Labarca and J. Quinn) and Paraguay (from J.M. Casellas and J.M. Casellas Jr.) which were con-firmed as PER-2 (M. Quinteros and J.M. Casellas, unpublished). PER-2-producing enteropathogenic E. coli were detected in isolates from Uruguay (Rodríguez et al., 2005) Interestingly and conversely with isolates harboring PER-1 enzymes, P. ae-ruginosa producing PER-2 have never been detected to our knowledge.

    While PER-1 has expanded to coun-tries distant from Turkey, such as France, Italy, Belgium and Korea (Paterson and Bonomo, 2005), PER-2 seems restricted to the southern cone of South America. CTX-M producers are frequently pres-ent in plasmids of typical Amp C produc-ers. This has been observed for more than 20 years in Argentina (Quinteros et al., 2003).

    Other ESBLsA huge number of other ESBLs have been recently discovered particularly in Asia but they are still infrequent at the moment. They include VEB, GES, BES, TLA, SFO, and IBC (Poirel et al., 1999; Paterson and Bonomo, 2005). We will not consider these ESBLs in the present review.

    Epidemiology and geographic distributions of ESBLsAs mentioned previously, the first reports of ESBLs came from Europe. French in-vestigators were particularly concerned with studying the clinical epidemiology and spread of ESBLs. Several reports from that country, especially by Brun-Buisson et al. (1987, 1989) describe outbreaks in dif-ferent intensive care units. The number of patients infected and the rate of dissemi-nation to different units and cities that oc-curred in the late 1980s was impressive.

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 10�

    Probably the same problem occurred in other countries as the USA but unfortu-nately the low interest in the detection of ESBLs in that country at that moment ac-counted for the huge differences in the in-cidence of ESBLs isolates between France and the USA.

    Undoubtedly, the spread of infections due to ESBLs producers is higher in coun-tries with lower economic resources. This is very clear when comparing incidence data from Sweden (3%) with those from Greece, Turkey or Portugal (> 25%) (Ilanberge et al., 1992; Paterson and Bonomo, 2005) or South America (> 30%) (Casellas, 1999; Quinteros et al., 2003). Notably, a survey from Turkey related to the incidence of Klebsiella spp. from intensive care units re-vealed that 58% of 193 isolates harbored ESBLs (Paterson and Bonomo, 2005).

    As stated, few clinicians were interest-ed in ESBLs in the USA. However, inves-tigators such as Bush, Bradford, Medeiros, Jacoby, Paterson, Yu, Sanders, Thomson, Quinn, Peterson, Rahal and others de-scribed outbreaks and set an alert about the spread of ESBLs in the USA (Quinn et al., 1989; Thomson and Sanders, 1992; Medeiros, 1997; Bush et al., 1995; Rahal et al., 1998; Bradford, 2001; Paterson et al., 2003; Paterson and Bonomo, 2005). At the moment CTX-M type ESBLs have been described in the USA and Canada and by no doubts these enzymes will fur-ther spread (Casellas, 1999; Paterson and Bonomo, 2005).

    The most impressive increase in ESBL infections, as well as detection of new en-zymes, occurs in South America and Asia, particularly from China (Chang et al., 2001). Among K. pneumoniae Chinese isolates, 25–38% proved to be ESBLs producers, particularly of SHV group en-zymes. Similar problems appear now in Korea. It is difficult to estimate how big is

    the ESBLs distribution in Asia since data from many crowded countries with low economic resources are missing (India, Thailand, Iraq, Iran, Mongolia) and, coinci-dentally, the imprudent use of antibacterial drugs in those countries appears to be the rule. As an example, CTX-M enzymes are by now spreading in Japan, India, China, Taiwan, and Korea (Cheng et al., 1994; Karim et al., 2001; Komatsu et al., 2001; Pai et al., 2001; Bell et al., 2002; Du et al., 2002; Yu et al., 2002; Wang et al., 2003). This seems coincident with the increasing use of generic ceftriaxone as happened in South America and East Europe (Casellas, 1999). In Australia the incidence of ESBLs is less than 5% and most of them belong to the SHV family (Paterson and Bonomo, 2005).

    The problem in Latin AmericaProbably the highest incidence of infec-tions due to ESBL-producing organisms is found in Latin America. Several reasons account for that, in addition to the poor social and economic conditions, and the high incidence of malnutrition, particular-ly among children: (1) crowded hospitals with frequently high patient/nurse ratios; (2) infrequent surveillance of antibiotic use; (3) self-prescription of antibiotics, as these drugs are sold over the counter in the whole region (except for Chile, Costa Rica, Cuba and, very recently, Venezuela); (4) deficient hospital hygiene, resulting in a high rate of Klebsiella spp. infections as well as colonization. This last one is a very important issue, as Klebsiella has the particular ability to acquire plasmids de-termining ESBL production. ESBL have been found in 30–60% of Klebsiella isolates from intensive care units in Argentina, Brazil, Colombia, and Venezuela (Casellas and Goldberg, 1989; Casellas et al., 1990;

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros110 |

    Guzmán Blanco et al., 2000; Casellas et al., 2003; Bonnet 2004).

    As stated before, the first ESBLs de-tected in Latin America were SHV types, in Chile and Argentina (Guzmán Blanco et al., 2000; Bonnet et al., 2000a). No TEM ESBLs were first reported in hu-mans in Argentina (Bauernfeind et al., 1992). Presently, CTX-M ESBLs are widely distributed in South American countries. PER-2 is restricted to the south cone of South America and particularly in Argentina (Rossi et al., 1995; Quinteros et al., 2003; Bonnet, 2004). Other CTX-M types (CTX-M-8, CTX-M-9, and CTX-M-16) have been detected in Brazil (Guzmán Blanco et al., 2000; Bonnet et al., 2000a, 2001; Poirel et al., 2000; Pessoa-Silva et al., 2004). Two non-TEM, non-SHV, non-CTX-M ESBLs have been re-cently reported from South America: GES-1 from Guiana (Mendes et al., 2000) and BES-1 from Brazil (Bonnet et al., 2000b). There are now more methods of assessing ESBL types and collaborative studies be-tween Latin American laboratories are in-creasing, which means that laboratories are no longer dependent on sending isolates to Europe or the USA, as in the past (Pfaller et al 1999a,b; Diekema et al., 1999; Sader et al., 2000a,b; Otman et al., 2002). ESBLs have been reported also from Mexico, Central America and Caribbean countries (González Vértiz et al., 2001; Chernian et al., 1999; Otman et al., 2002). However, the genotype of the isolates has not fre-quently been determined.

    Methods utilized for the detection of ESBLs

    Screening tests and phenotypic proceduresDetection of ESBLs is not routinely per-formed in many countries and even in the

    USA and Europe not more than half of the clinical laboratories perform tests to detect ESBL production by Enterobacteriaceae (Casellas et al., 2003; Jacoby and Muñoz-Price, 2005; Paterson and Bonomo, 2005). Moreover, ESBL producers are frequently reported as cefotaxime-susceptible, as was observed by Babbini and Livermore (2000) in a survey of Klebsiella spp. isolates col-lected from intensive care units in South-ern and Western Europe.

    Difficulties in screening for ESBLs are mostly due to the huge differences in breakpoints for cefotaxime, ceftazidime and aztreonam among different countries. As an example, susceptibility to cefotaxime varies from ≤ 1 mg/L in Spain, to ≤ 8 mg/L in the USA. The CLSI breakpoints for both cephalosporins and aztreonam were established in the early 80s prior to the dis-covery of ESBLs, and unfortunately these breakpoints were never changed. As point-ed out by Paterson et al. (2001) at that time, the clinical success against infections due to enteric bacteria with MICs of ≤ 8 mg/L was > 95%. The Argentinean Society for Clinical Bacteriology (SADEBAC) pro-posed, as early as 1998, a breakpoint of ≤ 2 mg/L for cefotaxime and ceftazidime as well as the equivalent diffusion break points and suggested that isolates with MICs ≥ 2 mg/L for these cephalosporins should be assayed for ESBL production.

    Screening testsCLSI proposed both disk diffusion and dilution methods in order to screen for ESBL production by Klebsiella spp. and Escherichia coli. In 2005, Proteus mirabilis was added to the group. For that purpose cefpodoxime, ceftazidime, cefotaxime or ceftriaxone, and aztreonam are used. Un-fortunately, CLSI suggestions have several pitfalls from our point of view:

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 111

    1 As suggested, any one of the aforemen-tioned antibacterial drugs is equally useful for screening purposes; this is not the SADEBAC’s opinion: as mentioned by Paterson and Bonomo (2005), more than one (we would say at least three) of these antimicrobials should be used.

    2 Moreover, we think that the use of ce-fepime is important since it is an excel-lent detector of most CTX-M ESBLs in AmpC producers.

    3 Disks containing 10 µg of cefpo-doxime have been recommended (Thomson and Sanders, 1992); how-ever, a break point of ≤ 22 mm lacks specificity (Tenover et al., 2003), and CLSI is now recommending a break point ≤ 17 mm.

    4 CLSI is reluctant to admit that Salmonella spp., Shigella spp. or other class A beta-lactamase producers should always be monitored for ESBL production; this is particularly im-portant in countries where Salmonella spp. and Shigella spp. are endemic, as in Latin American countries; CTX-M enzymes started most of their endem-ic distribution from Salmonella spp. infections (Casellas, 1999).

    5 the cefpodoxime dilution screen-ing test should use a breakpoint of ≥ 8 mg/L since most TEM-1 E. coli hyperproducers are resistant to 2 or 4 mg/L.

    6 it must be considered that many pos-sibilities do exist for obtaining an MIC result of ≥ 2 mg/L for cefotax-ime, cefriaxione or ceftazidime which are unrelated to ESBL production, as happens with hyperproduction of TEM-1 or SHV-1 or a combination of these with permeability or efflux related resistance; therefore, it must

    be kept in mind that the CLSI recom-mended screening tests are not confir-matory of ESBL production.

    Presumptive phenotypic tests for ESBL productionIn our understanding, there is no specific phenotypic confirmatory test for the de-tection of ESBL production. Phenotypic methods can in most instances bring a very high suspicion of the presence of an ESBL enzyme in a bacterial isolate, but ge-notypic methods often prove that the phe-notype-based suspicion is wrong. Probably the best and simpler phenotypic assay for the presumptive detection of ESBLs is the Jarlier test ( Jarlier et al., 1998) which is based in the observation, by Masuda et al. (1976) of the phenomena of enhanced zones when clavulanate disks are close to cefotaxime disks, due to the inhibitory ac-tivity of clavulanate against most ESBLs. The simplest test is, in our opinion, the dif-fusion method placing a disk of clavulanate close (20 mm edge to edge) to cefotaxime, ceftriaxone, ceftazidime, cefepime and az-treonam disks. However, technical prob-lems such as the adequate distance between disks are troublesome. Another method is based in comparing zones obtained with cefotaxime or ceftazidime 30 µg disks with similar disks soaked with 10 µg lithium clavulanate. This method was proposed by Casellas and Goldberg (1989): a difference of ≥ 4–5 mm for zones obtained with cla-vulanate combined disks as compared with zones of cephalosporins alone is consid-ered as a phenotypic presumption of ESBL production (Casellas et al., 2000).

    Our experience with broth microdilu-tion assays by automated methods is un-fortunate, since we observed failures due to TEM-1 or SHV-1 hyperproduction, as well as K. oxytoca K-1 hyperproduc-

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros11� |

    tion, in strains lacking ESBLs as assessed by genotypic methods. Failures with these methods can be as high as 13% (Casellas et al., 2000; Paterson and Bonomo, 2005). Conversely, we agree with Helfand and Bonomo (2005) that the most effective method to suggest the presence of ESBLs phenotypically, is the E-test, given its sim-plicity and reliability. Unfortunately, AB Biodisk requires the purchase of 100 strips for each antimicrobial drug, which is gener-ally unaffordable for most Latin American laboratories.

    Is it important to detect ESBLs production or is the MIC the only important data for the choice of antibacterial treatment?Enterobacterial ESBL producers show MIC values frequently high for 3GC, 4GC or aztreonam. The failure rate if patients infected with ESBL producers are treated with these drugs is high, near 100% in most cases (Meyer et al., 1993; Schiappa et al., 1996; Pai et al., 2001; Gupta et al., 2003; Paterson et al., 2004). Moreover, failures have also been observed when using 3GC or even 4GC to treat serious infections due to ESBL producers which MICs are in the “intermediate” or even in the higher end of the susceptible range ( Jett et al., 1995; Me-deiros and Crellin, 1997; Rice et al., 1991; Paterson et al., 2001). Nevertheless other investigators understood that if the MICs are sufficiently low (i.e., ≤ 1 mg/L for cefo-taxime or ceftriaxone, or ≤ 4 mg/L for ce-fepime) 3GC as well as 4GC could be used safely (W. Craig, Colombian Congress for Infectious Diseases, 2005). However, the critical question is about the routine phenotypic detection of ESBLs: Do the mechanisms of resistance not really matter, and the efforts for detecting ESBLs in the

    clinical laboratories must be reduced?. It must be considered that the benefits of de-termining MICs results rather than ESBLs detection has been showed in the murine thigh infection model, but not in humans (Andes and Craig, 2005).

    The most controversial issue is the clinical relevance of the inoculum effect. In vitro, cephalosporins MICs increase as the inoculum also increases. This has been observed with different ESBLs pro-ducers (Rice et al., 1991; Jett et al., 1995; Medeiros and Crellin, 1997; Casellas et al., 2003; Song et al., 2005). The differ-ences in MICs values for different inoc-ula can be impressive. For example, a K. pneumoniae strain producing a TEM-26 ESBL showed a MIC of 0.25 mg/L at an inoculum of 106 CFU/mL, which rose to 64 mg/L when using an inoculum of 107 CFU/mL (Queenan et al., 1996). These differences are both dependent on the type of BLA and the drug. We showed differ-ences as much of 4–6 dilutions in MICs against K. pneumoniae CTX-M-2 produc-ers when, tested against cefepime compar-ing 106 to 108 CFU/mL inocula. We must consider that serious deep infections (e.g., intrabdominal, meningitis, lower respi-ratory tract) occurred with bacterial vi-able populations of 108 CFU. We believe that prescribing ceftriaxone or cefotaxime when MICs are borderline, represents a high risk for treatment failure as these an-tibiotics do not always show optimal tis-sue penetration (Paterson and Bonomo, 2005). Quennan et al. (1996) showed that when performing microdilution tests with ESBL producers lowering the inocula 0.5 log resulted in false negative results. The arguments of Craig et al. (2004), suggest-ing that the inoculum effect is “an artifact rather than a fact” since it is related to the length of incubation in vitro for MICs or

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 11�

    time killing curves determinations are not quite convincing to us.

    However, the most important argu-ment in favor of continuous efforts in detecting ESBLs in human and veterinar-ian medicine is, as stated by Paterson and Bonomo (2005) that the simple report of an MIC can not warn of an outbreak due to ESBLs producing organisms and the corresponding need for appropriate infec-tion control interventions. We recently detected an outbreak in our institution by two clones of K. pneumoniae which includ-ed more than 30 isolates and affected 15 patients (Casellas et al., 2005). Detection was possible by ESBL phenotypic assay, but not always by the 3GC MICs.

    Treatment and outcome of infections due to ESBLs producersThere are no significant differences in mor-tality when comparing patients colonized or infected with ESBLs (De Champs et al., 1989, 1991; Piroth et al., 1998; Lautenbach et al., 2001; Gupta et al., 2003; Paterson et al., 2004). However, it must be considered that mortality is higher in bacteremic pa-tients (Schiappa et al., 1996) as we also showed in a recent outbreak at our insti-tution (Casellas et al., 2005). Mortality is obviously higher among patients who did not received adequate antibiotic therapy.

    As ESBLs are able to hydrolyze all available beta-lactam antibiotics, except for carbapenems and cephamycins, no beta-lactam drug other than carbapenems should be used even if it appears effective by sensitivity tests. Cephamycins must not be used in the treatment of infections caused by ESBL-producing organisms (Pangon et al., 1989; González Leiza et al., 1994; Bradford et al., 1997; Siu et al., 1999; Bradford, 2001; Casellas et al., 2003; Paterson and Bonomo, 2005). If not ac-

    companied by an AmpC enzyme, ESBL-producing isolates of Klebsiella spp., E. coli, Proteus mirabilis, salmonellae, etc. always appears susceptible to cephamycins; how-ever, we observed failures of cefoxitin treat-ments against ESBL producer infections. In one case, this was due to the in vivo acquisition of a plasmid-mediated AmpC by the etiological K. pneumoniae, which also lead to the discovery of a FOX-1 BLA (González Leiza et al., 1994). In other oc-casions, resistance rapidly occurred due to the selection of permeability mutants (Paterson and Bonomo, 2005). We not do recommend the use of cephamycins against infections caused by ESBL producers, even if susceptibility is documented.

    Another important point is that sev-eral resistance mechanisms can be found simultaneously in a single ESBL-produc-ing isolate, such as other chromosome- or plasmid-mediated BLAs (AmpC, TEM-1, SHV-1 or metallo-beta-lactamases), as well as efflux pumps, permeability or PBP alterations. It must be also considered that Klebsiella spp. often bear megaplasmids that mediate different drug resistance mechanisms. So, infections by ESBL pro-ducers can not be treated empirically with aminoglycosides, chloramphenicol, tetra-cyclines, trimethoprim, etc., which resis-tance determinants are commonly linked to ESBL genes. Resistance to fluoroquino-lones is also important, particularly among CTX-M producers (Casellas et al., 2003; Bonnet, 2004; Paterson and Bonomo, 2005). Colistin and polymixin B are very active against Klebsiella spp. and E. coli but not against Proteus spp. and importantly many infections caused by ESBL produc-ers are located in the lower respiratory tract where colistin is not particularly effective (Casellas, 2004; Falagas and Kasiakou, 2005).

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros11� |

    ESBL producers can be considered typically as multi-resistant bacteria; K. pneumoniae isolates are 12 times more likely to be multi-resistant as compared to E. coli isolates. This is important since 19 to 35% K. pneumoniae are ESBL produc-ers (Bradford, 2001; Casellas et al., 2003; Jacoby and Muñoz-Price, 2005; Helfand and Bonomo, 2005; Livermore and Hawkey, 2005). Another cause of concern is the observation that hypermutable E. coli strains were found more frequently found among ESBL producers than in nonpro-ducers (Baquero et al., 2005).

    Considering results of phase III tri-als, the new drug tigecycline should be useful for the treatment of serious ESBL infections. We have tested 50 ESBL pro-ducers and were susceptible to tigecycline with very low MIC values (< 1 mg/L). However, care must be taken in the use of this new drug in intensive care units, since it is not active against P. aeruginosa.

    Risk factors for ESBL acquisition: colonization and infectionIt is very important to differentiate coloni-zation from infection by ESBLs-producing bacteria. Data coming from bacteriological laboratories must be carefully analyzed by Infectious Diseases specialists, since many colonization cases end up considered as infections. As pointed by Paterson and Bonomo (2005), a plethora of studies used a case–control design to assess the risk fac-tors for colonization and infection with ESBLs-producing organisms, and results are conflictive and frequently confusing. However, some generalizations related to the patient’s risk of developing coloniza-tion or infection due to ESBLs producers can be established (Paterson et al., 2000, 2001, 2003; Paterson, 2002) as follows:

    1 Seriously ill patients with prolonged (> 15 days) hospital stay.

    2 Extended urinary tract catheteriza-tions.

    3 Extended (more than 10 days) place-ment of endotracheal tubes, central venous lines or nasogastric tubes (Asensio et al., 2000).

    4 Parenteral nutrition (Pena et al., 1997).

    5 Hemodyalisis (D’Agata et al., 1998).6 Decubit ulcers (Wiener et al., 1999).7 Excessive previous use of antibacte-

    rials, especially 3GC (Casellas et al., 1990; Fantin et al., 1990; Schiappa et al., 1996; Guzman Blanco et al., 2000; Bradford, 2001; Du et al., 2002; Bonnet et al., 2001; Paterson et al., 2001; Lautenbach et al., 2001; Eveillard et al., 2002; Kim et al., 2002a,b; Casellas et al., 2003; Paterson et al., 2003; Pessoa-Silva et al., 2004; Lee et al., 2004; Paterson et al., 2004; Paterson and Bonomo, 2005). Ceftriaxone has been particularly involved due to its high biliary excretion (Casellas et al., 1990; Casellas, 1999; Casellas et al., 2003). Also, from a survey at 15 USA hospitals, an association between az-treonam and cephalosporins use, and the emergence of ESBLs-producing organisms was found (Mavroidi et al., 2001).

    8 There is a striking association between the prolonged use of ciprofloxacin and colonization/infection by ESBL pro-ducers, as shown in a collaborative study involving 5 continents (Paterson et al., 2000).

    9 Nursing home stay, with some issues worth highlighting: (a) nursing homes are entirely different among coun-tries; in the USA, Europe and other countries, they are like hotels, while in most Latin American countries (par-

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 11�

    ticularly Argentina) they resemble jails; (b) medical care and nursery also differs completely; in many of our geriatric institutions, patients suffer urinary catheterization just for nurs-es comfort; (c) in most LA nursing homes, antibiotics are given without medical prescription, ceftriaxone be-ing favorite due to the possibility to use as an OD intramuscular dose, and at low cost; (d) patients coming from nursing homes may have not recently or never been hospitalized, but many of them circulate continuously from nursing homes to hospitals and vice versa. In a recent survey at Buenos Aires we found that 48% of patients from nursing homes were carriers of ESBL producers, as detected in urine or feces (unpublished).

    Control of ESBL-related outbreaksOutbreak infections can be either mono-clonal or polyclonal. When monoclonal, outbreaks are caused by patient-to-pa-tient or patient-healthcare personnel–pa-tient transmission. Oppositely, polyclonal nosocomial outbreaks are generally due to pitfalls in antibiotic use or control. Conse-quently, monoclonal infections require ad-ditional care of barrier measures, infection control and surveillance cultures, while polyclonal infections demands actions of the Antibiotic Use Committee in the hos-pital.

    In the past, biotyping, antibiotyping, serotyping and even phagotyping, were used in order to determine the clonal type of an outbreak. These methods are no lon-ger appropriate but for screening isolates to choose which ones to compare. In the case of antibiotyping, care must be taken with frozen isolates, as plasmid lose is not rare. Currently, molecular methods are preferred

    as epidemiological tools. Most are plasmid profile analysis; the simplest is to visualize plasmids using pulse-field gel electrophore-sis (PFGE). PFGE of chromosomal DNA is however the preferred method and the gold standard for genotyping ESBL pro-ducers (Venazia et al., 1995; Prodinger et al., 1996; Rice et al., 1996; Ardanuy et al., 1998; Rahal et al., 1998; Siu et al., 1999; Stewart and Lessing, 1999; Paterson and Bonomo, 2005). If ribotyping is avail-able, this is a very useful method for typ-ing ESBLs as well as several PCR-derived methods. As it is not the purpose of this chapter to deal with molecular methods we refer the reader to the excellent reviews by Paterson and Bonomo (2005) as well as from Jacoby and Muñoz-Price (2005).

    Once the outbreak is deemed mono-clonal or polyclonal, the bacterial spread within the hospital must be addressed. K. pneumoniae, a common ESBL producer, is particularly able to survive in hospital fomites, and desiccation nor high hu-midity are an inconvenience for them, so they are frequently found in thermom-eters and bronchoscopes. Prevalence of K. pneumoniae in hospitals, especially Latin American ones, increases because of some peculiar practices: (a) bronchoscopes and uroscopes are frequently sterilized in our hospitals with glutaraldehyde, but only for 15 minutes, which is not enough; pneu-mologists and urologists claim that both instruments are tarnished by a larger expo-sure; (b) sink basins are a frequent cause of permanence of K. pneumoniae in in-tensive care units; The reason seems to be the positive electric charges of the metallic basins, which attracts the negative charges of the external membrane (G. Tomé and J.M. Casellas, unpublished data); (c) cock-roaches are also a frequent cause of trans-mission of acinetobacters, P. aeruginosa and K. pneumoniae; the three species are able

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros11� |

    to use chitin as carbon source. Many Latin American hospitals, but especially those in the southern cone of South America, are full of cockroaches. In a hospital where one of us has worked since 2001 in San Isidro, Argentina, the same Acinetobacter baumannii clone isolated from cockroaches collected nearby the ICU was also cultured from the hands of health care personnel, infected patients, and fomites (Casellas J M., Gliosca L. and Tomé, unpublished data). This was also observed by Cotton et al. (2000); (d) Klebsiella spp. are highly resistant to soap, and soap is frequently re-utilized in some Latin American hospitals, this being also a cause of ESBL producer dissemination.

    Undoubtedly the transient carriage of bacteria producing ESBLs in the hands of health personnel is the most important method of transfer of ESBLs producers from patient to patient and has been fully documented (Eisen et al., 1995; Radice et al., 2001; Paterson and Bonomo, 2005; Casellas et al., 2005). Even though most Argentinean outbreaks of ESBLs start by intestinal transmission in the community (Bauernfeid et al., 1992), this does not seem to be an important cause of dissemination at the hospital (Paterson and Bonomo, 2005), although fecal transmission has been observed (Mhamd et al., 1999).

    When an outbreak occurs we recom-mend to inoculate hands and feces swabs on MacConkey agar supplemented with 2 mg/L cefotaxime and 5 mg/L vancomy-cin. We do not use amphotericin B. This media is not in accordance with the one suggested by Green and Barbaroda (1998), who disregard the possibility of the isola-tion of CTX-M enzymes, as they use cef-tazidime. Therefore we do not recommend ceftazidime media in countries where CTX-M ESBLs are prevalent.

    Finally, to solve the problem of endem-ic colonization, the best approach is prob-ably to review infection control measures and introduce piperacillin–tazobactam in the formulary. In nursery homes the use of ertapenem is also recommended even though the emergency of P. aeruginosa outbreaks should be carefully controlled; if CTX-M ESBLs are not prevalent, ce-fepime could be another choice.

    A new challenge: ESBLs in community-acquired infectionsCuriously, ESBLs in community-acquired (CA) infections appeared almost at the same time as CA-methicillin-resistant Staphylococcus aureus. Coincidence or not, it is a serious problem. Most community-acquired ESBLs in Latin America and in other developing countries are reported amongst Salmonella spp. and Shigella spp. isolates (Casellas and Goldberg, 1989; Bauernfeind et al., 1992; Bonnet et al., 2001; Fortineau et al., 2001; Aitmhand et al., 2002; Baraniak et al., 2002; Jacoby et al., 2003; Kruger et al., 2004). However, in the last years several reports of community acquired E. coli and K. pneumoniae not re-lated to nursery homes or hospitals have been published. Reports came from Spain, France, Israel, UK and Canada (Mirelis et al., 2003; Colodner et al., 2004; Mundai et al., 2004; Rodríguez Bano et al., 2004; Blomberg et al., 2005; Brigante et al., 2005; Arpin et al., 2005). In the last year at least two or three community-acquired infec-tions due to ESBLs producers are detected in our institution. Relation of these strains with foodstuff have been postulated (Pa-terson and Bonomo, 2005), but we also found pet carriage of these isolates (un-published).

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 117

    ReferencesAitMhand, R., Soukri, A., Moustaoui, N.,

    Amarouch, H., ElMdaghri, N., Sirot, D., and Benbachir, M. (2002). Plasmid mediated TEM-3 extended-spectrum beta lactamase production in Salmonella typhimurium in Casablanca. J. Antimicrob. Chemother. 49, 169–172.

    Ambler, R.P., Coulson A.F., Frere, J., Ghuisen, J., Joris, B., Forsman, M., Levesque, R., Tiraby, G., and Waley, S. (1992). A standard number-ing scheme for the class A beta-lactamases. Biochem. J. 276, 269–270.

    Andes, D., and Craig, W.A. (2005). Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic con-siderations. Clin. Microbiol. Infect. 6, 10–17

    Ardanuy, C., Liñares, J., Domínguez, S.A., Hernández-Alles, S., Benedi, V.J., and Martínez Martínez, L. (1998). Outer mem-brane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob. Agents Chemother. 42, 1636–1640.

    Arpin, C., Dubois, V., Maugein, J., Jullin, J., Dutilh, B., Brochet, J., Larribet, G., Fisher, B. and Quentin, C. (2005). Clinical and molecular analysis of extended spectrum beta lactamase producing enterobacteria in the community setting. J. Clin. Microbiol. 43, 5048–5054.

    Asensio, A., Oliver, A., González Diego, P., Baquero, F., Pérez Díaz, J.C., Ros, P., Covo, J., Palacios, M., LasHeras, D., Cantón, R. (2000). Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: an-tibiotic use as risk factor for colonization and infection. Clin. Infect. Dis. 30, 55–60.

    Babini, G.S., and Livermore, D.M. (2000). Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998. J. Antimicrob. Chemother. 45, 183–189.

    Baquero, M.R., Galán, J.C., Turrientes, M.C., Cantón, R., Coque, T., Martínez, J., Baquero, F. (2005). Increased mutation frequencies in Escherichia coli isolates harboring extended-spectrum beta lactamases. Antimicrob. Agents Chemother. 49, 4754–4756.

    Baraniak, A., Sadowy, E., Hryeniewicz, W., and Gniadkowski, M. (2002). Two different ex-tended spectrum beta lactamases (ESBLs) in one of the first ESBL-producing Salmonella isolates in Poland. J. Clin. Microbiol. 40, 1095–1097.

    Bauernfeind, A., Casellas, J.M., Goldberg, M., Holley, M., Jungwirth, R., Mandgold, P., Rohnisch, T., Schweighart, S., and Wilhelm, R. (1992). A new plasmidic cefotaximase from patients infected with Salmonella typhimurium Infection. 20, 158–163.

    Bauernfeind, A., Stemplinger, R., Jungwirth, P., Mangold, P., Amann, S., Akalin, S., Ang, O., Bal, C., and Casellas, J.M. (1996). Characterization of beta-lactamase gene bla-PER2, which encodes an extended-spectrum class A beta-lactamase. Antimicrob. Agents Chemother. 40, 509–513.

    Bell, J.M., Turnidge, D., Gales, A.C., Pfaller, M.A., and Jones, R.N. (2002). Prevalence of extended spectrum beta-lactamase (ESBL) producing clinical isolates in the Asia Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance pro-gram (1998–99). Diagn. Microbiol. Infect Dis. 42, 193–198.

    Blomberg, B., Jureen, R., Manji, K.P., Tamim, B.S., Mwakagile, D.S., Urassa, K., Fataki, M., Msangi, V., Tellevik, M.G., Maselle, S.Y., and Langeland, N. (2005). High rate of fatal cases of pediatric septicemia caused by Gram nega-tive bacteria with extended spectrum beta lac-tamases in Dar es Salaam, Tanzania. J. Clin. Microbiol. 43, 745–749.

    Bonnet, R. (2004). Growing group of extended-spectrum beta-lactamases. The CTX-M en-zymes. Antimicrob Agents Chemother. 48, 1–14.

    Bonnet, R., Dutour, C., Sampaio, J.L., Chanal, C., Sirot, D., Labia, R., De Champs, C., and Sirot, J. (2001). Novel cefotaximases (CTX-M-16) with increased catalytic efficiency due to sub-stitution Asp-240→Gly. Antimicrob. Agents Chemother. 45, 2269–2275.

    Bonnet, R., Sampaio, J.L., Chanal, C., Sirot, C., De Champs, C., Viallart, J.L., Labia, R., and Sirot, J. (2000a). A novel class A extended-spectrum beta lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob. Agents Chemother. 44, 3061–3068.

    Bonnet, R., Sampaio, J.L., Labia, R., De Champs, C., Sirot, D., Chanal, D., and Sirot, J. (2000b). A novel CTX-M beta lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob. Agents Chemother. 44, 1936–1942.

    Bradford, P.A., Urban, C., Mariano, N., Projan, S.J., Rahal, J.J., and Bush, K. (1997). Imipenem resistance in Klebsiella pneumoniae is associat-ed with the combination of ACT-1, a plasmid mediated AmpC beta lactamase, and the loss

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros11� |

    of an outer membrane protein. Antimicrob. Agents Chemother. 41, 563–569.

    Bradford, P.A. (2001). Extended spectrum beta-lactamases in the 21st century: characteriza-tion, epidemiology and detection of this im-portant resistance threat. Clin. Microbiol. Rev. 48, 933–951.

    Brigante, G., Luzzaro, F., Perilli, M., Lombardi, G., Coli, A., Rosselini, M., Amicosante, G., and Toñolo, A. (2005). Evolution of CTX-M type beta lactamases in isolates of Escherichia coli infecting hospital and community patients. Int. J. Antimicrob. Agents. 25, 157–162.

    Brun-Buisson, C., Legrand, C.P., Philippon, A., Montravers, F., Ansquer, M., and Duval, J. (1987). Transferable enzymatic resistance to third-generation cephalosporins during a nos-ocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 2, 302–306.

    Brun-Buisson, C., Legrand, C.P., Rauss, A., Richard, C., Montravers, F., Besbes, M., Meakins, J.L., Soussy, J.C., and Lemaire, F. (1989). Intestinal decontamination for control of nosocomial multiresistant Gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann. Intern. Med. 110, 873–881.

    Bush, K., Jacoby, G.A. and Medeiros, A.A. (1995). A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39, 1211–1233.

    Casellas, J.M. (1999). South America: A differ-ent continent, different ESBLs. J. Antimicrob. Chemother. 44 (suppl. A), 16.

    Casellas, J.M. (2004)., Colistina. Su resurrección en el siglo 21. Rev. Antimicrob. Latinoam. (in Spanish) 1, 1–18.

    Casellas, J.M., and Goldberg, M. (1989). Incidence of strains producing extended spectrum beta-lactamases in Argentina. Infection 17, 434–436.

    Casellas, J.M., Goldberg, M., Morosini, M., Negri, M.C., Arduino, S. (1990). Estudios sobre cepas productoras de beta lactamasas plasmídicas de espectro extendido en Argentina. Infect. Microbiol. Clin. (in Spanish) 2, 23–35.

    Casellas, J.M., Guzmán-Blanco, M., and Pinto, M.E. (1994). The sleeping giant: antimicrobi-als resistance. Infect. Dis. Clin. North Am. 8, 29–46.

    Casellas, J.M., Nannini, E., Radice, M., Cocconi, E., and Lejona, S. (2005). An outbreak of ex-tended spectrum beta lactamase producers in a health care center from Rosario, Argentina. Rev. Panam. Infect. (in Spanish) 50, 229–230.

    Casellas, J.M., Radice, M., Quinteros, M.G., Power, P., Rodríguez, M., Pagniez, G., Tomé,

    G., Couto, E., Gutkind, G. (2000). Valor de distintos métodos para la detección de beta lactamasas de espectro extendido en entero-bacterias. Res. Infect. Vacunas (in Spanish) 1, 23.

    Casellas, J.M., Tomé, G., Bantar, C., Bertolini, P., Blázquez, N., Borda, N., Couto, E., Cudmani, N., Guerrera, J., Juárez, M.J., López, T., Littvik, A., Méndez, E., Notario, R., Ponce, G., Quinteros, M., Salamone, F., Sparo, M., Sutich, E., Vaylet, S., and Wolff, L. (2003). Argentinean collaborative multicenter study on the in vitro comparative activity of piper-acillin–tazobactam against selected bacterial isolates recovered from hospitalized patients. Diag. Microb. Infect. Dis. 47, 247–257.

    Chang, F.Y., Siu, K., Fung, C.P., Huang, H., and Ilo, M. (2001). Diversity of SHV and TEM beta lactamase in Klebsiella pneumoniae gene evolution in northern Taiwan and two novel beta lactamases, SHV-25 and SHV-26. Antimicrob. Agents Chemother. 45, 2407–2413.

    Cheng, Y., Li, Y., and Chen, M. (1994). A plasmid-mediated SHV type extended-spectrum beta lactamase in Beijing isolate of Enterobacter ger-goviae. Wei Sheng Wu Xue Bao. 34, 106–112.

    Cherian, B.P., Singh, N., Charles, W., and Prabhakar, P. (1999). Extended-spectrum beta-lactamase-producing Salmonella enter-itidis in Trinidad and Tobago. Emerg. Infect. Dis. 5, 181–182.

    Colodner, R., Rock, W., Chazan, B., Keller, N., Guy, N., Sakran, W., and Paz, R. (2004). Risk factors for the development of extended spectrum beta lactamase producing bacte-ria in nonhospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23, 163–167.

    Cotton, M.F., Wasserman, E., Pieper, C. H., Theron, D.C., van Tubbergh, D., Campbell, G., Fang, C., and Barnes, J. (2000). Invasive disease due to extended spectrum beta lac-tamase producing Klebsiella pneumoniae in a neonatal unit: the possible role of cockroaches. J. Hosp. Infect. 44, 13–17.

    Craig, N., Bahvnani, S.N., and Ambrose, P.G. (2004). The inoculum effect, fact or artifact. Diagn. Microb. Infect. Dis. 50, 229–230.

    D´Agata, E.L., Venkataraman, L., DeGirolami, P., Weigel, L., Samore, M., and Tenover, F. (1998). The molecular and clinical epidemiol-ogy of Enterobacteriaceae producing extend-ed-spectrum beta lactamase in a tertiary care hospital. J. Infect. 36, 279–285.

    Datta N., and Kontomichalou, P. (1965). Penicillase synthesis controlled by infectious

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 11�

    R factors in Enterobacteriaceae. Nature 208, 239–241.

    Decousser, J.W., Poirel, L., and Nordmann, P. (2001). Characterization of a chromosomally encoded extended-spectrum class A beta-lac-tamase from Kluyvera cryocrescens. Antimicrob. Agents Chemother. 45, 3595–3598.

    De Champs, C., Rouby, D., Guelon, D., Sirot, G., Sirot, D., Beytout, D., and Gourgant, J.M. (1991). A case–control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta lac-tamase. J. Hosp. Infect. 18, 5–13.

    De Champs, C., Sauvant, M.P., Chanal, C., Sirot, D., Gazuy, N., Maihurer, R., Baguet, J.C., and Sirot, J. (1989). Prospective survey of coloni-zation and infection caused by expanded-spec-trum beta lactamase producing members of the family Enterobacteriaceae in an intensive care unit. J. Clin. Microbiol. 27, 2887–2890.

    Diekema, D.J., Pfaller, M.A., Jones, R.N., Doern, G.V., Winokur, P.L., Gales, A.C., Sader, H.S., Kugler, K., and Beach, M. (1999). Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimi-crobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29, 595–607.

    Du, B., Long, Y., Liu, H., Chen, D., Liu, D., Xu, Y., and Xie, X. (2002). Extended-spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 28, 1718–1723.

    Eisen, D., Russell, G., Tymms, M., Roper, E.J., Grayson, L., and Turnidge, J. (1995). Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant Klebsiella pneumoniae. J. Clin. Microbiol. 33, 713–717.

    Eveillard, M., Schmit, J.L., and Eb, F. (2002). Antimicrobial use prior to the acquisition of multiresistant bacteria. Infect. Control Hosp. Epidemiol. 23, 155–158.

    Falagas, M., and Kasiakou, S. (2005). Colistin: The revival of polymixins for the management of multidrug resistant Gram negative bacterial infections. Clin. Infect. Dis. 40, 1303–1311.

    Fantin, B., Pangon, B., Potel, G., Caron, F., Vallee, E., Valtois, J.M., Mohler, J., Bure, A., Philippon, A., and Carbon, C. (1990). Activity of sulbac-tam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2 like beta

    lactamase. Antimicrob. Agents Chemother. 34, 581–586.

    Fortineau, N., Naas, T., Gaillot, O., and Nordmann, P. (2001). SHV-type extended spectrum beta lactamase in a Shigella flexneri clinical isolate. J. Antimicrob. Chemother. 47, 685–688.

    Garau, G., García-Sáez, I., Bebrone, C., Anne, C., and Mercuri, P. (2004). Update of the standard numbering scheme for class B beta-Lactamases. Antimicrob. Agents Chemother. 48, 2347–2349.

    González-Leiza, M., Pérez-Díaz, J.C., Ayala, J., Casellas, J.M., Martínez Beltrán, J., Bush, K., and Baquero, F. (1994). Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae a new AmpC type plas-mid mediated beta lactamase. Antimicrob. Agents Chemother. 38, 2150–2157.

    González-Vértiz, A., Alcántar-Curiel, D., Cuauhtli, M., Daza, C., Gayosso, C., Solache, C., Horta, C., Mejía, F., Santos, J.I., and Alpuche-Aranda, C. (1994). Multiresistant extended-spectrum beta lactamase-produc-ing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infections. Infect. Control Hosp. Epidemiol. 22, 723–725.

    Green, M., and Barbaroda, K. (1998). Recovery of ceftazidime-resistant Klebsiella pneumoniae from pediatric liver and intestinal transplant recipients. Pediatr. Transplant. 2, 224–230.

    Gupta, A., Della-Latta, B., Todd, P., San Gabriel, J., Haas, F., Wu, D., Rubenstein, D., and Saiman, L. (2003). Outbreak of extended-spectrum beta lactamases producing Klebsiella pneumoniae in a neonatal intensive care unit. Infect. Central Hosp. Epidemiol. 24, 356.

    Guzmán Blanco, M., Casellas, J.M., and Silva Sader, H. (2000). Bacterial resistance to anti-microbial agents in Latin America: the giant is awakening. Infect. Dis. Clin. N. Am. 14, 67–82.

    Helfand, M.S., and Bonomo, R.A. (2005). Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta lactamases and metallobeta lactamases on the treatment of resistant Gram negative pathogens. Curr. Opin. Pharmacol. 5, 452–458.

    Huang, W., Petrosino, J., Hirsch, M., Shenkin, P.S., and Palzkill, T. (1996). Amino acid se-quence determinants of beta-lactamase struc-ture and activity. J. Mol. Biol. 258, 688–703.

    Humeniuk, G.C., Gaulier, V., Grimont, P., Labia, R. and Philippon, A. (2002). Beta lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types.

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros1�0 |

    Antimicrob. Agents Chemother. 46, 3045–3049.

    Ilanberge, J.L., García Rodríguez, J.A., Gobernado, M., Goossens, J.L., Nilsson, L.E., and Struelens, M.J. (1992). Antibiotic suscep-tibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. J. Am. Med. Asoc. 281, 67–71.

    Jacoby, G.A. (1994). Genetic of extended spec-trum beta lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 13, 2–11.

    Jacoby, G.A., and Muñoz-Price, L.S. (2005). The new beta lactamases. N. Engl. J. Med. 352, 380–391.

    Jacoby, G.A., Chow, N., and Waites, K.B. (2003). Prevalence of plasmid-mediated quinolone re-sistance. Antimicrob. Agents Chemother. 47, 559–562.

    Jarlier, V., Nicolas, M. H., Fournier, G., and Philippon, A. (1998). Extended broad-spec-trum beta-lactamase conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns: Rev. Infect. Dis. 10, 867–878.

    Jett, B.D., Ritchie, D.J., Reichley, R., Bailey, T.C., and Sahm, D.F. (1995). In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp resistant to oxyimino cephalo-sporins. Antimicrob. Agents Chemother. 39, 1187–1190.

    Karim, A., Piorel, L., Nagarajal, S., and Nordman, P. (2001). Plasmid mediated extended-spec-trum beta lactamase (CTX-M3 like) form India and gene association with insertion se-quence ISPEcp1. FEMS Microbiol. Lett. 201, 237–241.

    Kim, B.N., Woo, J. H., Kim, M.N., Ryu, J., and Kim, Y.S. (2002). Clinical implications of extended-spectrum beta lactamase produc-ing Klebsiella pneumoniae bacteremia. J. Hosp. Infect. 52, 99–106.

    Kim, Y.K., Pai, H., Lee, J. H., Park, S.E., Choi, E. H., Kim, J., and Kim, E.C. (2002). Bloodstream infections by extended-spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiol-ogy and clinical outcome. Antimicrob. Agents Chemother. 46, 1481–1491.

    Kliebe, C., Nies, B.A., Meyer, F., Tolxdorff-Neutzling, R.M., and Wiedemann, B. (1985). Evolution of plasmid coded resistance to broad spectrum cephalosporins. Antimicrob. Agents Chemother. 28, 302–307

    Knothe, H., Shah, P., Krcmery, V., Antal, M. and Mitsuhashi, S. (1983). Transferable resistance to cefotaxime, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 11, 315–317

    Komatsu, M., Ikeda, N., Aihara, M., Nakamachi, Y., Kinoshita, S., Yamasaki, K., and Shimakawa, K. (2001). Hospital outbreak of MEN-1-derived extended spectrum beta lactamase-producing Klebsiella pneumoniae. J. Infect. Chemother. 7, 94–101.

    Knox, J.R. (1995). Extended-spectrum and in-hibitor-resistant TEM type beta-lactamases, mutations, specificity and 3-dimensional structure. Antimicrob. Agents Chemother. 39, 2593–2601.

    Kruger, T., Szabo, D., Keddy, K. H., Deeley, K., Marsh, A., Hujer, A.M., Bonomo, R., and Paterson, D. (2004). Infections with nonty-phoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob. Agents Chemother. 48, 4263–4270.

    Lautenbach, E., Patel, J.B., Bilker, W.B., Edelstein, P. H., and Fishman, N.O. (2001). Extended-spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on out-comes. Clin. Infect. Dis. 32, 1288–1294.

    Lee, S.O., Lee, E.S., Park, S.Y., Kim, S.Y., Seo, Y. H., and Cho, Y.K. (2004). Reduced use of third generation cephalosporins decreases the acquisition of extended-spectrum beta lactamase producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25, 832–837.

    Livermore, D. (1995). Beta-lactamases in labora-tory and clinical resistance. Clin. Microbiol. Rev. 8, 557–584.

    Livermore, D., and Hawkey, P.M. (2005). CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56, 451–454.

    Masuda, G., Tomioka, S., and Hasegawa, M. (1976). Detection of beta lactamase produc-tion by Gram negative bacteria. J. Antibiot. 29, 662–664.

    Mavroidi, A., Tzelepi, E., Tsakris, A., Miriagou, V., Sofianou, D., and Yzouvelekis, L.S. (2001). An integron-associated beta lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended spectrum beta lactamase IBC-1. J. Antimicrob. Chemother. 48, 627–630.

    Medeiros, A.A. (1997). Evolution and dissemina-tion of beta-lactamases accelerated by genera-tions of beta lactams antibiotics. Clin. Infect. Dis. 24 (suppl 1), 519–545.

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 1�1

    Medeiros, A.A., and Crellin, J. (1997). Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula. Pedriatr. Infect. Dis. 16, S49–55

    Mendes, C., Hsiung, A., Kiffer, C., Oplustil, C., Sinto, S., Mimica, I., and Zoccoli, C. (2000). Evaluation of the in vitro activity of 9 antimi-crobials against bacterial strains insolated from patients in intensive care in Brazil: MYSTIC Antimicrobial Surveillance Program. Braz. J. Infect. Dis. 4, 236–244.

    Meyer, K.S., Urban, C., Eagan, J.A., Berger, B.J., and Rahal, J.J. (1993). Nosocomial outbreak of Klebsiella infection resistant to late-genera-tion cephalosporins. Ann. Intern. Med. 119, 353–358.

    Mhand, R,A., Brahimi, N., Moustaoui, N., El Mdaghri, N., Amarouch, H., Grimont, F., Bingen, F., and Benbachir, M. (1999). Characterization of extended spectrum beta lactamase producing Salmonella typhimurium by phenotypic and genotypic typing methods. J. Clin. Microbiol. 37, 3769–3773.

    Mirelis, B., Navarro, F., Miro, E., Mesa, R.J., Coll, P., and Prats, G. (2003). Community trans-mission of extended-spectrum beta lactamase. Emerg. Infect. Dis. 9, 1024–1025.

    Munday, C.J., Whitehead, G.M., Todd, N.J., Campbell, M., and Hawkey, P.M. (2004). Predominance and genetic diversity of com-munity and hospital acquired CTX-M ex-tended-spectrum beta lactamases in York, UK. J. Antimicrob. Chemother. 54, 628–633.

    Nordman, P., and Nass, T. (1994). Sequence analysis of PER-1 extended-spectrum beta lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob. Agents Chemother. 38, 104–114.

    Oliver, A., Pérez Díaz, J.C., Coque, T.M., Baquero, F., and Cantón, R. (2001). Nucleotide se-quence and characterization of a novel cefo-taxime-hydrolyzing beta lactamase (CTM-X-10) isolated in Spain. Antimicrob. Agents Chemother. 45, 616–620.

    Otman, J., Cavassin, E.D., Perugini, M.E., and Vidotto, M.C. (2002). An outbreak of ex-tended-spectrum beta-lactamase-produc-ing Klebsiella species in a neonatal intensive care unit in Brazil. Infect. Control Hosp. Epidemiol. 23, 8–9.

    Pai, H., Choi, E. H., Lee, H.J., Hong, J.Y., Jacoby, G.A. (2001). Identification of CTX-M-14 extended-spectrum beta lactamase in clini-cal isolates of Shigella sonnei, Escherichia coli,

    and Klebsiella pneumoniae in Korea J. Clin. Microbiol. 39, 3747–3749.

    Pangon, B., Bizet, C., Bure, A., Pichon, F., Philippon, A., Regnier, B. and Gutmann, L. (1989). In vivo selection of a cephamycin-re-sistant, porin-deficient mutant Klebsiella pneu-moniae producing TEM-3 beta lactamase. J. Infect. Dis. 159, 1005–1006

    Paterson, D.L. (2002). Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin. Infect. Dis. 34, 1564–1567.

    Paterson, D.L., and Bonomo R.A. (2005). Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657–686.

    Paterson, D.L., Hujer, K.M., Yeiser, B., Bonomo, M.D., Rice, L., Bonomo, R.A. (2003). Extended-spectrum beta lactamases in Klebsiella pneumoniae bloodstreams iso-lates from seven countries: Dominance and widespread prevalence of SHV and CTX-M type beta lactamase. Antimicrob. Agents Chemother. 47, 3554–3560.

    Paterson, D.L, Ko, W.C., Von Gottberg, A., Casellas, J.M., Mulazimoglu, L., Klugman, K., Bonomo, R., Rice, L., McCormack, J., and Yu, L. (2001). Outcome of cephalosporin treat-ment for serious infections due to apparently susceptible organism producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39, 2206–2212.

    Paterson, D.L., Ko, W.C., Von Gottberg, A., Mohapatra, S., Casellas, J.M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K., Bonomo, R., Rice, L., Wagener, M.M., McCormack, G., and Yu, L.V. (2004). Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of ex-tended-spectrum beta lactamases. Clin. Infect. Dis. 39, 31–37.

    Paterson, D.L., Mulazimoglu, L., Casellas, J.M., Ko, W.C., Goossens, H., Von Gottherg, A., Mohapatra, S., Trenholme, G., Klugman, K., McCormack, J.G., and Yu, V. (2000). Epidemiology of ciprofloxacin resistance and its relationship to extended spectrum beta lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30, 473–478.

    Pessoa-Silva, C.L., Meurer Moreira, B., Câmara Almeida, V., Flannery, B., Almeida Lins, M.C., Mello Sanpaio, J., Martins Texeira, L., Vaz Miranda, L., Riley, L., and Gerbelding, J.L. (2004). Extended-spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal intensive care unit: risk factors for infection

  • Uncorrected proofs — not for distribution

    Casellas and Quinteros1�� |

    and colonization. J. Hosp. Infect. 53, 198–206.

    Pena, C., Pujol, M., Ricart, A., Ardanuy, C., Ayats, J., Liñares, J., Garrigosa, F., Ariza, J., and Gudiol, F. (1997). Risk for factors for faccal carriage of Klebsiella pneumoniae producing extended-spectrum beta lactamase (ESBL-KP) in the intensive care unit. J. Hosp. Infect. 35, 9–16.

    Petroni, A., Corso, A., Melano, R., Cacace, M.L., Brun, A M., Rossi, A., and Galas, M. (2002). Plasmidic extended-spectrum beta-lac-tamases in Vibrio cholerae O1 El Tor isolates in Argentina. Antimicrob. Agents Chemother. 46, 1462–1468.

    Pfaller, M.A., Jones, R.N., and Doern, G.V. (1999). Multicenter evaluation of the antimi-crobial activity for six broad-spectrum beta lactamases in Venezuela: comparison of data from 1997 and 1998 using the E-test method. Diagn. Microbiol. Infect Dis. 35, 153–158.

    Pfaller, M.A., Jones, R.N., Doern, G.V., and Salasar, J.C. (1999). Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta lactamase in Colombia: comparison of data 1997 and 1998 using the Etest method. Diagn. Microbiol. Infect. Dis. 35, 235–241.

    Piroth, L., Aube, H., Doise, J.M., and Vicent-Martin, M. (1998). Spread of extended-spec-trum beta lactamase producing Klebsiella pneu-moniae: are beta lactamase inhibitors of thera-peutic value? Clin. Infect. Dis. 27, 76–80.

    Poirel, L., Kampfer, P., and Nordmann, P. (2002). Chromosome-encoded Ambler class A beta-lactamase of Kluyvera georgeana, a probable progenitor of a subgroup of CTX-M extend-ed-spectrum beta-lactamases. Antimicrob. Agents Chemother. 46, 4038–4040.

    Poirel, L., Le Thomas, I., Naas, T., Karim, A., Nordmann, P. (2000). Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44, 622–632.

    Poirel, L., Lebessi, M., Castro, C., Fevre, C., Foustoukou, M., and Nordmann, P. (2004). Nosocomial outbreak of extended-spectrum beta lactamase SHV-5 producing isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrob. Agents Chemother 48, 2277–2279.

    Poirel, L., Naas, T., Guibert, M., Chaibi, E.B., Labia, R., and Nordmann, P. (1999). Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lac-tamase encoded by an Escherichia coli integron

    gene. Antimicrob. Agents Chemother. 43, 573–581.

    Prodinger, W.M., Fille, M., Bauernfeind, A., Stemplinger, I., Amann, S., Pfauster, B., Lass-Florl, G., and Dierich, M.P. (1996). Molecular epidemiology of Klebsiella pneumoniae pro-ducing SHV-5 beta lactamase: parallel out-breaks due to multiple plasmid transfer. J. Clin. Microbiol. 34, 564–568.

    Queenan, A.M., Foleno, B., Gownley, C., Wira, E., and Bush, K. (1996). Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneu-moniae clinical isolates tested by using National Committee for Clinical Laboratory Standards ESBL methodology. J. Clin. Microbiol. 42, 269–275

    Quinn, J.P., Miyashiro, D., Sahro, D., Flamm, R., and Bush, K. (1989). Novel plasmid-mediated beta lactamase (TEM 10) conferring selec-tive resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 33, 1451–1456.

    Quinteros, M., Radice, M., Power, P., Callejo, R., Hirsch, R., Couto, E., and Gutkind G. (2000). Natural dissemination of CTXM beta lactamases to Aeromonas hydrophila. 9th International Congress on Infectious Diseases. Abstract 74020. Buenos Aires, Argentina.

    Quinteros, M., Radice, M., Gargella, N., Rodriguez, M., Costa, N., Korbenfeld, D., Couto, E., and Gutkind, G. (2003). Extended-spectrum beta lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother. 47, 2864–2867.

    Radice, M., Power, P., Di Conza, J., Gutkind, G., Bonnet, R., Sirot, D., Sirot, J., and Labia, R. (2002). Early dissemination of CTX-M-de-rived enzymes in South America. Antimicrob. Agents Chemother. 46, 602–604.

    Radice, M., González, C., Power, P., Vidal, M.C., and Gutkind, G. (2001). Third generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg. Infect. Dis. 7, 442–443.

    Rahal, J.J., Urban, C., Horn, D., Freeman, K., Segal-Maurer, S., Maurer, J., Mariano, M., Marks, S., Burn, J.M., Dominick, D., and Lim, M. (1998). Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella J. Am. Med. Asoc. 280, 1233–1237.

    Rice, L.B., Eckstein, E.C., DeVente, J., and Shlaes, D.M. (1996). Ceftazidime resistant Klebsiella pneumoniae isolates recovered at the Cleveland

  • Uncorrected proofs — not for distribution

    A Latin American “Point de Vue” | 1��

    Department of Veterans Affairs Medical Center. Clin. Infect. Dis. 23, 118–124.

    Rice, L.B., Yao, J.D., Klimm, K., Eliopoulos, G.M., and Moellering, R.C. (1991). Efficacy of differ-ent beta lactams against an extended-spectrum beta lactamase-producing Klebsiella pneumoni-ae strains in the rat intra-abdominal abscess model. Antimicrob. Agents Chemother. 35, 1243–1244.

    Rodríguez, C., Radice, M., Perazzi, B., Castro, S., Juárez, J., Santini, P., Vay, C., Famiglietti, A., and Gutkind, G. (2005). Resistencia enz-imática a betalactámicos en el género Proteus y evaluación de los fenotipos y genotipos de resistencia a cefalosporinas de tercera y cuarta generación en Proteus mirabilis. Enfermedades Infec. Microbiol. (in Spanish) 3, 122.

    Rodríguez-Bano, J., Navarro, M.D., Romero, L., Martínez-Martínez, L., Muniain, M.A., Perea, E., Pérez-Cano, R., and Pascual, A. (2004). Epidemiology and clinical features of infections caused by extended-spectrum beta lactamase producing Escherichia coli in non-hospitalized patients: J. Clin. Microbiol. 42, 1089–1094.

    Rossi, A., Lopardo, H., Woloj, M., Picandet, A.M., Marino, M., Galas, M., Radice, M., Gutkind, G. (1995). Non-typhoid Salmonella spp resis-tant to cefotaxime. J. Antimicrob. Chemother. 36, 697–702

    Sader, H.S., Gales, A.C., Granacher, T.D., Pfaller, M.A., and Jones, R.N. (2000a). Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997–98). Braz. J. Infect. Dis. 4, 245–254.

    Sader, H.S., Jones, R.N., Gales, A.C., Winokur, P., Kugler, K.C., Pfaller, M.A., and Doern, G.V. (2000b). Antimicrobial susceptibility patterns for pathogens isolates from patients in Latin America medical centers with a diag-nosis of pneumonia: analysis of a result from the SENTRY Antimicrobial Surveillance Program 1997. SENTRY Latin America Study Group. Diagn. Microbiol. Infect. Dis. 32, 289–301.

    Schiappa, D.A., Hayden, M.K., Matushek, M.G., Hashemi, F.N., Sullivan, J., Smith, K., Miyashiro, D., Quinn, J., Weinstein, R., and Trenholme, G. (1996). Ceftazidime-resis-tant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case control and mo-lecular epidemiologic investigation. J. Infect. Dis. 174, 529–536.

    Siu, L.K., Lu, P.L., Hsueh, P.R., Lin, F.M., Chang, S.C., Luh, K.T., Ho, M., and Lee, C.Y. (1999). Bacteremia due to extended-spectrum beta

    lactamase producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J. Clin. Microbiol. 37, 4020–4027.

    Song, W., Moland, E., Hanson, N., Lewis, J., Jorgensen, J., and Thomson, K.S. (2005). Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J. Clin. Microbiol. 43, 4891–4894.

    Stewart, B.A., and Lessing, M.P. (1999). A hos-pital outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae. J. Hosp. Infect. 41, 71–72.

    Tenover, F.C., Raney, P.M., Williams, P.P., Rasheed, J.K., Biddle, J.W., Oliver, A., Fridkin, S.K., Jevitt, L., McGowan, J.E. Jr, and Project ICARE. (2003). Evaluation of the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase confir-mation methods for Escherichia coli with iso-lates collected during Project ICARE. J. Clin. Microbiol. 41, 3142–3146.

    Thomson, K.S., and Sanders, C.C. (1992). Detection of extended-spectrum beta lactamases in members of the family Enterobacteriaceae: comparison of the double disk and three dimensional tests. Antimicrob. Agents Chemother. 36, 1877–1882.

    Tzouvelekis, L.S., Tzelepi, E., Tassios, P.T., and Legakis, N.J. (2000). CYM-X-type beta-lac-tamase an emerging group of extended-spec-trum enzymes. Int. J. Antimicrob. Agents 14, 137–142.

    Vahaboglu, H., Coskunkan, F., Tansel, O., Ozturk, R., Sahin, N., Koksal, I., Kocazeybek, B., Tatman-Otkun, M., Leblebicioglu, H., Ozinel, M.A., Akalin, H., Kocagoz, S., and Korten, V. (2001). Clinical importance of extended-spec-trum beta-lactamase (PER-1-type) producing Acinetobacter spp and Pseudomonas aeruginosa strains J. Med Microbiol. 50, 64